文献速递造血干细胞移植与细胞治疗

抑制JARID2重编程人造血祖细胞以增强骨髓移植

JARID2 inhibition reprograms human hematopoietic progenitor cells to enhance bone marrow transplantation.
PubMed 文献 · Blood Adv · 2026-01-01

该研究探讨抑制JARID2能否增强人脐带血造血干祖细胞功能。体外和体内实验显示,JARID2敲低增加细胞数量并提升功能,机制涉及STAT1上调驱动的静息样长期自我更新程序。提示JARID2抑制是可逆的体外扩增策略。

要点

  • JARID2敲低可增加人脐带血造血干祖细胞数量并增强其体内外功能。
  • 该效应不依赖JARID2的PRC2辅因子活性,与EZH2抑制不同。
  • 机制涉及STAT1上调驱动的静息样长期自我更新基因程序。

核心结论

  • 抑制JARID2可增强人脐带血来源造血干祖细胞的体外和体内功能,为扩大移植细胞来源提供新思路。

研究设计与样本

  • 研究在人脐带血来源造血干祖细胞中采用持续性和短暂性JARID2敲低,并与人脐带血细胞中EZH2抑制进行对比。

主要发现

  • JARID2敲低在体外和体内均增加人造血干祖细胞数量并增强其功能。
  • 该表型与EZH2抑制不同,提示机制不依赖JARID2的PRC2辅因子活性。
  • JARID2敲低促进由STAT1上调驱动的静息、长期自我更新基因表达程序,并伴随MHC II类免疫表型。
  • 类似小鼠机制,上述效应在体内赋予人MPP以HSC样潜能。

临床怎么用

  • JARID2抑制可作为体外扩增功能性脐带血造血干祖细胞的可逆策略,有望扩大移植供者来源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematopoietic stem cell (HSC) transplantation is a common treatment for many blood disorders and can be a lifesaving therapy for patients with leukemias, lymphomas, and multiple myeloma. Umbilical cord blood (UCB) serves as a valuable source of hematopoietic stem and progenitor cells (HSPCs) for transplantation, particularly for patients lacking a matched donor. However, the limited number of repopulating cells in UCB units restricts its clinical utility. Our prior studies showed that the genetic deletion of the polycomb repressive complex 2 (PRC2) cofactor Jarid2 in mouse multipotent progenitors (MPPs) conveyed ectopic self-renewal capacity. Here, we hypothesized that the function of human HSPCs could be enhanced through JARID2 inhibition. In this study, we demonstrate that both constitutive and transient knockdown (KD) of JARID2 increases the number and enhances the functionality of human HSPCs both in vitro and in vivo. This phenotype was distinct from the inhibition of EZH2 in UCB cells, suggesting that the mechanism was independent of the PRC2 cofactor activity of JARID2. Mechanistically, JARID2 KD promotes a quiescent, long-term self-renewal gene expression program governed by STAT1 upregulation and characterized by an MHC class II immunophenotype. Analogous to mice, these mechanisms conferred HSC-like potential to human MPPs in vivo. Taken together, these findings highlight JARID2 inhibition as a novel and reversible approach to expand functional UCB-derived HSPCs ex vivo, potentially improving access to stem cell transplantation for a wider patient population.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Han W, Bjeije H, Celik H, et al. JARID2 inhibition reprograms human hematopoietic progenitor cells to enhance bone marrow transplantation. Blood Adv. 2026. PMID: 42486681. doi:10.1182/bloodadvances.2025019220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。